Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

NewAmsterdam Pharma Company NV (OQ:NAMS)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: Gooimeer 2-35
NAARDEN 1411 DC
Tel: N/A
Website: https://ir.newamsterdampharma.com
IR: See website
Key People
Michael Harvey Davidson
Chief Executive Officer, Executive Director
Michael Harvey Davidson
Chief Executive Officer, Executive Director
Louise Kooij
Interim Chief Financial Officer
Louise Kooij
Interim Chief Financial Officer
Douglas Kling
Chief Operating Officer
Douglas Kling
Chief Operating Officer
John Kastelein
Chief Scientific Officer, Non-Executive Director
John Kastelein
Chief Scientific Officer, Non-Executive Director
Juliette Audet
Chief Business Officer
Juliette Audet
Chief Business Officer
Marc Ditmarsch
Chief Development Officer
Marc Ditmarsch
Chief Development Officer
Business Overview
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer's disease. The Company strives to offer its products around the world.
Financial Overview
For the three months ended 31 March 2024, NewAmsterdam Pharma Company NV revenues decreased 84% to $1.4M. Net loss increased from $42M to $93.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Fair value change earnout and warrants increase from $6.2M to $39M (expense).